Deletion of CB2 cannabinoid receptor induces schizophrenia-related behaviors in mice

Neuropsychopharmacology

Volumn 36, Issue 7, 2011, Pages 1489-1504

  Ortega Alvaro, Antonio ^a   Aracil Fernández, Auxiliadora ^b,c   García Gutiérrez, María S ^b,c   Navarrete, Francisco ^b,c   Manzanares, Jorge ^b,c  

^a HOSPITAL GENERAL UNIVERSITARIO DE ALBACETE   (Spain)

^b MIGUEL HERNÁNDEZ UNIVERSITY   (Spain)

^c INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

cannabinoid; CB2 receptor; schizophrenia; risperidone; pre pulse inhibition; gene expression

Indexed keywords

ALPHA 2C ADRENERGIC RECEPTOR; CANNABINOID 2 RECEPTOR; COCAINE; DOPAMINE 2 RECEPTOR; RISPERIDONE; SEROTONIN 2A RECEPTOR; CATECHOLAMINE RECEPTOR; NEUROLEPTIC AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANXIETY; ARTICLE; BEHAVIOR DISORDER; COGNITIVE DEFECT; CONTROLLED STUDY; DEPRESSION; DORSAL RAPHE NUCLEUS; GENE DELETION; GENE EXPRESSION; LOCUS CERULEUS; MALE; MAZE TEST; MOOD DISORDER; MOTOR ACTIVITY; MOUSE; NONHUMAN; OPEN FIELD TEST; PREFRONTAL CORTEX; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCHIZOPHRENIA; ANALYSIS OF VARIANCE; ANIMAL; AUDITORY STIMULATION; AVOIDANCE BEHAVIOR; C57BL MOUSE; CLASSIFICATION; DARK ADAPTATION; DISEASE MODEL; DRUG EFFECT; EXPLORATORY BEHAVIOR; GENE EXPRESSION REGULATION; GENETICS; IMMOBILIZATION; INHIBITION (PSYCHOLOGY); MEMORY DISORDER; METABOLISM; METHODOLOGY; MOUSE MUTANT; PHYSIOLOGY; SENSORY GATING; TIME;

ACOUSTIC STIMULATION; ANALYSIS OF VARIANCE; ANIMALS; ANTIPSYCHOTIC AGENTS; ANXIETY; AVOIDANCE LEARNING; COGNITION DISORDERS; DARK ADAPTATION; DEPRESSION; DISEASE MODELS, ANIMAL; EXPLORATORY BEHAVIOR; GENE EXPRESSION REGULATION; HINDLIMB SUSPENSION; INHIBITION (PSYCHOLOGY); MALE; MAZE LEARNING; MEMORY DISORDERS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; RECEPTOR, CANNABINOID, CB2; RECEPTORS, CATECHOLAMINE; RISPERIDONE; SCHIZOPHRENIA; SENSORY GATING; TIME FACTORS;

EID: 79955983779     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/npp.2011.34     Document Type: Article

References (102)

1. Abi-Dargham A, Laruelle M (2005). Mechanisms of action of second generation antipsychotic drugs in schizophrenia: insights from brain imaging studies. Eur Psychiatry 20: 15-27. (Pubitemid 40092387)
2. Abood M, Barth F, Bonner TI, Cabral G, Casellas P, Cravatt BF et al (2010a). Cannabinoid receptors: CB1. Last modified on 2010-06-2. http://www.iuphar-db.org/DATABASE/ObjectDisplayForward? objectId / 56. (accessed on 19-08-2010. IUPHAR database (IU-PHAR-DB)).
3. Abood M, Barth F, Bonner TI, Cabral G, Casellas P, Cravatt BF et al (2010b). Cannabinoid receptors: CB2. Last modified on 2010-06-29. http://www.iuphar-db.org/DATABASE/ObjectDisplay Forward?objectId/57. (accessed on 19-08-2010. IUPHAR database (IUPHAR-DB)).
4. Andreasson S, Allebeck P, Engstrom A, Rydberg U (1987). Cannabis and schizophrenia. A longitudinal study of Swedish conscripts. Lancet 2: 1483-1486.
5. Atwood BK, Mackie K (2010). CB2: a cannabinoid receptor with an identity crisis. Br J Pharmacol 160: 467-479.
6. Barbier E, Wang J (2009). Anti-depressant and anxiolytic like behaviors in PKCI/HINT1 knockout mice associated with elevated plasma corticosterone level. BMC Neuroscience 10: 132.
7. Barbier E, Zapata A, Oh E, Liu Q, Zhu F, Undie A et al (2007). Supersensitivity to amphetamine in protein kinase-C interacting protein//HINT1 knockout mice. Neuropsychopharmacology 32: 1774-1782. (Pubitemid 47076381)
8. Barnett JH, Werners U, Secher SM, Hill KE, Brazil R, Masson K et al (2007). Substance use in a population-based clinic sample of people with first-episode psychosis. Br J Psychiatry 190: 515-520. (Pubitemid 46868836)
9. Bégou M, Volle J, Bertrand JB, Brun P, Job D, Schweitzer A et al (2008). The stop null mice model for schizophrenia displays cognitive and social deficits partly alleviated by neuroleptics. Neuroscience 157: 29-39.
10. Bersani G, Orlandi V, Kotzalidis GD, Pancheri P (2002). Cannabis and schizophrenia: impact on onset, course, psychopathology and outcomes. Eur Arch Psychiatry Clin Neurosci 252: 86-92. (Pubitemid 36056682)
11. Bohme GA, Laville M, Ledent C, Parmentier M, Imperato A (1999). Enhanced long-term potentiation in mice lacking cannabinoid CB1 receptors. Neuroscience 95: 5-7.
12. Braff D, Geyer M, Swerdlow N (2001). Human studies of prepulse inhibition of startle: normal subjects, patient groups, and pharmacological studies. Psychopharmacology 156: 234-258. (Pubitemid 32705488)
13. Buckland PR, D'Souza U, Maher NA, McGuffin P (1997). The effects of antipsychotic drugs on the mRNA levels of serotonin 5HT2A and 5HT2C receptors. Mol Brain Res 48: 45-52. (Pubitemid 27298127)
14. Buckley NE, McCoy KL, Mezey E, Bonner T, Zimmer A, Felder CC et al (2000). Immunomodulation by cannabinoids is absent in mice deficient for the cannabinoid CB(2) receptor. Eur J Pharmacol 396: 141-149. (Pubitemid 30265571)
15. Burnet PWJ, Chen CPLH, McGowan S, Franklin M, Harrison PJ (1996). The effects of clozapine and haloperidol on serotonin-1A, -2A and -2C receptor gene expression and serotonin metabolism in the rat forebrain. Neuroscience 73: 531-540. (Pubitemid 26168807)
16. Crawley J, Goodwin FK (1980). Preliminary report of a simple animal behavior model for the anxiolytic effects of benzodiaze-pines. Pharmacol Biochem Behav 13: 167-170. (Pubitemid 11225713)
17. D'Souza DC, Abi-Saab WM, Madonick S, Forselius-Bielen K, Doersch A, Braley G et al (2005). Delta-9-tetrahydrocannabinol effects in schizophrenia: implications for cognition, psychosis, and addiction. Biol Psychiatry 57: 594-608. (Pubitemid 40409699)
18. De Marchi N, De Petrocellis L, Orlando P, Daniele F, Fezza F, Di Marzo V (2003). Endocannabinoid signalling in the blood of patients with schizophrenia. Lipids Health Dis 2: 5.
19. 3H]CP-55940 binding in the human central nervous system: regional specific changes in density of cannabinoid-1 receptors associated with schizophrenia and cannabis use. Neuroscience 103: 9-15. (Pubitemid 32304342)
20. Delotterie D, Ruiz G, Brocard J, Schweitzer A, Roucard C, Roche Y et al (2010). Chronic administration of atypical antipsychotics improves behavioral and synaptic defects of STOP null mice. Psychopharmacology 208: 131-141.
21. Desbonnet L, Waddington JL, O'Tuathaigh CMP (2009). Mutant models for genes associated with schizophrenia. Biochem Soc Trans 037: 308-312.
22. Dyck BA, Skoblenick KJ, Castellano JM, Ki K, Thomas N, Mishra RK (2009). Behavioral abnormalities in synapsin II knockout mice implicate a causal factor in schizophrenia. Synapse 63: 662-672.
23. Egashira N, Tanoue A, Higashihara F, Fuchigami H, Sano K, Mishima K et al (2005). Disruption of the prepulse inhibition of the startle reflex in vasopressin V1b receptor knockout mice: reversal by antipsychotic drugs. Neuropsychopharmacology 30: 1996-2005. (Pubitemid 43093500)
24. Fernandez-Ruiz J, Romero J, Velasco G, Tolon RM, Ramos JA, Guzman M (2007). Cannabinoid CB2 receptor: a new target for controlling neural cell survival? Trends Pharmacol Sci 28: 39-45. (Pubitemid 46038536)
25. Franowicz JS, Kessler LE, Borja CMD, Kobilka BK, Limbird LE, Arnsten AFT (2002). Mutation of the alpha 2A-adrenoceptor impairs working memory performance and annuls cognitive enhancement by guanfacine. J Neurosci 22: 8771-8777. (Pubitemid 35387619)
26. Gainetdinov RR, Wetsel WC, Jones SR, Levin ED, Jaber M, Caron MG (1999). Role of serotonin in the paradoxical calming effect of psychostimulants on hyperactivity. Science 283: 397-401.
27. Galve-Roperh I, Aguado T, Palazuelos J, Guzman M (2008). Mechanisms of control of neuron survival by the endocannabi-noid system. Curr Pharm Des 14: 2279-2288.
28. Garća-Gutiérrez MS, Manzanares J (2011). Overexpression of CB2 cannabinoid receptor gene decreased vulnerability to anxiety and impaired anxiolytic action of alprazolam in mice. J Psychopharmcol 25: 111-120.
29. Garcia-Gutierrez MS, Perez-Ortiz JM, Gutierrez-Adan A, Manzanares J (2010). Depression-resistant endophenotype in mice overexpressing cannabinoid CB(2) receptors. Br J Pharmacol 160: 1773-1784.
30. Giakoumaki SG, Roussos P, Rogdaki M, Karli C, Bitsios P, Frangou S (2007). Evidence of disrupted prepulse inhibition in unaffected siblings of bipolar disorder patients. Biol Psychiatry 62: 1418-1422. (Pubitemid 350180720)
31. Giuffrida A, Leweke FM, Gerth CW, Schreiber D, Koethe D, Faulhaber J et al (2004). Cerebrospinal anandamide levels are elevated in acute schizophrenia and are inversely correlated with psychotic symptoms. Neuropsychopharmacology 29: 2108-2114. (Pubitemid 39486563)
32. Goncalves MB, Suetterlin P, Yip P, Molina-Holgado F, Walker DJ, Oudin MJ et al (2008). A diacylglycerol lipase-CB2 cannabinoid pathway regulates adult subventricular zone neurogenesis in an age-dependent manner. Mol Cell Neurosci 38: 526-536.
33. Gong JP, Onaivi ES, Ishiguro H, Liu QR, Tagliaferro PA, Brusco A et al (2006). Cannabinoid CB2 receptors: immunohistochemical localization in rat brain. Brain Res 1071: 10-23. (Pubitemid 43255471)
34. Gray L, Van den Buuse M, Scarr E, Dean B, Hannan AJ (2009). Clozapine reverses schizophrenia-related behaviours in the metabotropic glutamate receptor 5 knockout mouse: association with N-methyl-D-aspartic acid receptor up-regulation. Int J Neuropsychopharmacol 12: 45-60.
35. Halene TB, Ehrlichman RS, Liang Y, Christian EP, Jonak GJ, Gur TL et al (2009). Assessment of NMDA receptor NR1 subunit hypofunction in mice as a model for schizophrenia. Genes Brain Behav 8: 661-675.
36. Han L, Picker JD, Schaevitz LR, Tsai G, Feng J, Jiang Z et al (2009). Phenotypic characterization of mice heterozygous for a null mutation of glutamate carboxypeptidase II. Synapse 63: 625-635.
37. Harkany T, Guzman M, Galve-Roperh I, Berghuis P, Devi LA, Mackie K (2007). The emerging functions of endocannabinoid signaling during CNS development. Trends Pharmacol Sci 28: 83-92. (Pubitemid 46161836)
38. Hattori S, Murotani T, Matsuzaki S, Ishizuka T, Kumamoto N, Takeda M et al (2008). Behavioral abnormalities and dopamine reductions in sdy mutant mice with a deletion in Dtnbp1, a susceptibility gene for schizophrenia. Biochem Biophys Res Commun 373: 298-302.
39. Herkenham M, Lynn AB, Johnson MR, Melvin LS, de Costa BR, Rice KC (1991). Characterization and localization of cannabi-noid receptors in rat brain: a quantitative in vitro autoradio-graphic study. J Neurosci 11: 563-583.
40. Herkenham M, Lynn AB, Little MD, Johnson MR, Melvin LS, de Costa BR et al (1990). Cannabinoid receptor localization in brain. Proc Natl Acad Sci USA 87: 1932-1936.
41. Hoffman HS, Ison JR (1980). Reflex modification in the domain of startle: I. Some empirical findings and their implications for how the nervous system processes sensory input. Psychol Rev 87: 175-189.
42. Hsu R, Woodroffe A, Lai W-S, Cook MN, Mukai J, Dunning JP et al (2007). Nogo receptor 1 (RTN4R) as a candidate gene for schizophrenia: analysis using human and mouse genetic approaches. PLoS ONE 2: e1234.
43. Huang X-F, Han M, Huang X, Zavitsanou K, Deng C (2006). Olanzapine differentially affects 5-HT2A and 2C receptor mRNA expression in the rat brain. Behav Brain Res 171: 355-362. (Pubitemid 43946500)
44. Ikeda M, Hikita T, Taya S, Uraguchi-Asaki J, Toyo-oka K, Wynshaw-Boris A et al (2008). Identification of YWHAE, a gene encoding 14-3-3epsilon, as a possible susceptibility gene for schizophrenia. Hum Mol Genet 17: 3212-3222.
45. Ishiguro H, Horiuchi Y, Ishikawa M, Koga M, Imai K, Suzuki Y et al (2010). Brain cannabinoid CB2 receptor in schizophrenia. Biol Psychiatry 67: 974-982.
46. Ishiguro H, Iwasaki S, Teasenfitz L, Higuchi S, Horiuchi Y, Saito T et al (2006). Involvement of cannabinoid CB2 receptor in alcohol preference in mice and alcoholism in humans. Pharmacoge-nomics J 7: 380-385.
47. Iyer S, Boekestyn L, Cassidy C, King S, Joober R, Malla A (2008). Signs and symptoms in the pre-psychotic phase: description and implications for diagnostic trajectories. Psychol Med 38: 1147-1156. (Pubitemid 351950151)
48. Izquierdo I, Medina JH, Izquierdo LA, Barros DM, de Souza MM, Mello e Souza T (1998). Short- and long-term memory are differentially regulated by monoaminergic systems in the rat brain. Neurobiol Learn Mem 69: 219-224. (Pubitemid 28374557)
49. Karl T, Duffy L, Scimone A, Harvey RP, Schofield PR (2007). Altered motor activity, exploration and anxiety in heterozygous neuregulin 1 mutant mice: implications for understanding schizophrenia. Genes Brain Behav 6: 677-687. (Pubitemid 47476190)
50. Katona I, Freund TF (2008). Endocannabinoid signaling as a synaptic circuit breaker in neurological disease. Nat Med 14: 923-930.
51. Kishi T, Moriwaki M, Kitajima T, Kawashima K, Okochi T, Fukuo Y et al (2010). Effect of aripiprazole, risperidone, and olanzapine on the acoustic startle response in Japanese chronic schizophrenia. Psychopharmacology 209: 185-190.
52. Kvajo M, McKellar H, Arguello PA, Drew LJ, Moore H, MacDermott AB et al (2008). A mutation in mouse Disc1 that models a schizophrenia risk allele leads to specific alterations in neuronal architecture and cognition. Proc Natl Acad Sci USA 105: 7076-7081. (Pubitemid 351754532)
53. Leweke FM, Giuffrida A, Wurster U, Emrich HM, Piomelli D (1999). Elevated endogenous cannabinoids in schizophrenia. NeuroReport 10: 1665-1669. (Pubitemid 29354290)
54. Lister RG (1987). The use of a plus-maze to measure anxiety in the mouse. Psychopharmacology 92: 180-185. (Pubitemid 17072893)
55. Martin M, Ledent C, Parmentier M, Maldonado R, Valverde O (2002). Involvement of CB1 cannabinoid receptors in emotional behaviour. Psychopharmacology 159: 379-387. (Pubitemid 34143362)
56. Martinez-Gras I, Rubio G, del Manzano BA, Rodriguez-Jimenez R, Garcia-Sanchez F, Bagney A et al (2009). The relationship between prepulse inhibition and general psychopathology in patients with schizophrenia treated with long-acting risperidone. Schizophr Res 115: 215-221.
57. McCormick PN, Kapur S, Graff-Guerrero A, Raymond R, Nobrega JN, Wilson AA (2010). The antipsychotics olanzapine, risperidone, clozapine, and haloperidol are D2-selective ex vivo but not in vitro. Neuropsychopharmacology 35: 1826-1835.
58. Meltzer HY, Huang M (2008). In vivo actions of atypical antipsychotic drug on serotonergic and dopaminergic systems. In: Di Giovanni G, Di Matteo V, Esposito E (eds). Progress in Brain Research, Vol 172, Elsevier: Amsterdam. pp 177-197.
59. Mohn AR, Gainetdinov RR, Caron MG, Koller BH (1999). Mice with reduced NMDA receptor expression display behaviors related to schizophrenia. Cell 98: 427-436. (Pubitemid 29402481)
60. Morgan CJ, Curran HV (2008). Effects of cannabidiol on schizophrenia-like symptoms in people who use cannabis. Br J Psychiatry 192: 306-307. (Pubitemid 351692406)
61. Moriwaki M, Kishi T, Takahashi H, Hashimoto R, Kawashima K, Okochi T et al (2009). Prepulse inhibition of the startle response with chronic schizophrenia: a replication study. Neurosci Res 65: 259-262.
62. Munro S, Thomas KL, Abu-Shaar M (1993). Molecular characterization of a peripheral receptor for cannabinoids. Nature 365: 61-65. (Pubitemid 23305569)
63. Nagai H, Egashira N, Sano K, Ogata A, Mizuki A, Mishima K et al (2006). Antipsychotics improve [Delta]9-tetrahydrocannabinol-induced impairment of the prepulse inhibition of the startle reflex in mice. Pharmacol Biochem Behav 84: 330-336. (Pubitemid 44107489)
64. Onaivi ES (2009). Cannabinoid receptors in brain: pharmaco-genetics, neuropharmacology, neurotoxicology, and potential therapeutic applications. In: Hari Shanker S (ed.). International Review of Neurobiology Vol 88, Academic Press: New York. pp 335-369.
65. Onaivi ES, Carpio O, Ishiguro H, Schanz N, Uhl GR, Benno R (2008). Behavioral effects of CB2 cannabinoid receptor activation and its influence on food and alcohol consumption. Ann N Y Acad Sci 1139: 426-433.
66. Onaivi ES, Ishiguro H, Gong JP, Patel S, Perchuk A, Meozzi PA et al (2006). Discovery of the presence and functional expression of cannabinoid CB2 receptors in brain. Ann N Y Acad Sci 1074: 514-536. (Pubitemid 44532857)
67. Palazuelos J, Aguado T, Egia A, Mechoulam R, Guzman M, Galve-Roperh I (2006). Non-psychoactive CB2 cannabinoid agonists stimulate neural progenitor proliferation. FASEB J 20: 2405-2407.
68. Palkovits M (1983). Punch sampling biopsy technique. Methods Enzymol 103: 368-376.
69. Paxinos G, Franklin KBJ (2001). The Mouse Brain in Stereotaxic Coordinates. Academic Press, Harcourt Science and Technology Company: New York.
70. Peralta V, Campos MS, Garća de Jalón E, Cuesta MJ (2010). Motor behavior abnormalities in drug-näve patients with schizophrenia spectrum disorders. Mov Disord 25: 1068-1076.
71. Perona MT, Waters S, Hall FS, Sora I, Lesch KP, Murphy DL et al (2008). Animal models of depression in dopamine, serotonin, and norepinephrine transporter knockout mice: prominent effects of dopamine transporter deletions. Behav Pharmacol 19: 566-574.
72. Perry W, Minassian A, Paulus MP, Young JW, Kincaid MJ, Ferguson EJ et al (2009). A reverse-translational study of dysfunctional exploration in psychiatric disorders: from mice to men. Arch Gen Psychiatry 66: 1072-1080.
73. Powell SB, Young JW, Ong JC, Caron MG, Geyer MA (2008). Atypical antipsychotics clozapine and quetiapine attenuate prepulse inhibition deficits in dopamine transporter knockout mice. Behav Pharmacol 19: 562-565.
74. Puig MV, Watakabe A, Ushimaru M, Yamamori T, Kawaguchi Y (2010). Serotonin modulates fast-spiking interneuron and synchronous activity in the rat prefrontal cortex through 5-HT1A and 5-HT2A receptors. J Neurosci 30: 2211-2222.
75. Quérée P, Peters S, Sharp T (2009). Further pharmacological characterization of 5-HT2C receptor agonist-induced inhibition of 5-HT neuronal activity in the dorsal raphe nucleus 'in vivo'. Br J Pharmacol 158: 1477-1485.
76. Racz I, Nadal X, Alferink J, Banos JE, Rehnelt J, Martin M et al (2008). Crucial role of CB2 cannabinoid receptor in the regulation of central immune responses during neuropathic pain. J Neurosci 28: 12125-12135.
77. Ralph RJ, Paulus MP, Fumagalli F, Caron MG, Geyer MA (2001). Prepulse inhibition deficits and perseverative motor patterns in dopamine transporter knock-out mice: Differential effects of D1 and D2 receptor antagonists. J Neurosci 21: 305-313. (Pubitemid 32098754)
78. Rapoport JL, Addington AM, Frangou S, Psych MR (2005). The neurodevelopmental model of schizophrenia: update 2005. Mol Psychiatry 10: 434-449. (Pubitemid 40646432)
79. Reibaud M, Obinu MC, Ledent C, Parmentier M, Böhme GA, Imperato A (1999). Enhancement of memory in cannabinoid CB1 receptor knock-out mice. Eur J Pharmacol 379: R1-R2. (Pubitemid 29492956)
80. Rojas P, Joodmardi E, Hong Y, Perlmann T, Ogren SO (2007). Adult mice with reduced Nurr1 expression: an animal model for schizophrenia. Mol Psychiatry 12: 756-766. (Pubitemid 47172691)
81. Ross CA, Margolis RL, Reading SA, Pletnikov M, Coyle JT (2006). Neurobiology of schizophrenia. Neuron 52: 139-153. (Pubitemid 44466356)
82. Sakae N, Yamasaki N, Kitaichi K, Fukuda T, Yamada M, Yoshikawa H et al (2008). Mice lacking the schizophrenia-associated protein FEZ1 manifest hyperactivity and enhanced responsiveness to psychostimulants. Hum Mol Genet 17: 3191-3203.
83. Sallinen J, Haapalinna A, Viitamaa T, Kobilka BK, Scheinin M (1998). Adrenergic alpha 2C-receptors modulate the acoustic startle reflex, prepulse inhibition, and aggression in mice. J Neurosci 18: 3035-3042. (Pubitemid 28163233)
84. Schmittgen TD, Zakrajsek BA, Mills AG, Gorn V, Singer MJ, Reed MW (2000). Quantitative reverse transcription-polymerase chain reaction to study mRNA decay: comparison of endpoint and real-time methods. Anal Biochem 285: 194-204.
85. Schotte A, Bonaventure P, Janssen PFM, Leysen JE (1995). In vitro receptor binding and in vivo receptor occupancy in rat and guinea pig brain: Risperidone compared with antipsychotics hitherto used. Jpn J Pharmacol 69: 399-412. (Pubitemid 26013775)
86. Sugranyes G, Flamarique I, Parellada E, Baeza I, Goti J, Fernandez-Egea E et al (2009). Cannabis use and age of diagnosis of schizophrenia. Eur Psychiatry 24: 282-286.
87. Swerdlow NR, Keith VA, Braff DL, Geyer MA (1991). Effects of spiperone, raclopride, SCH 23390 and clozapine on apomor- phine inhibition of sensorimotor gating of the startle response in the rat. J Pharmacol Exp Ther 256: 530-536.
88. Szumlinski KK, Lominac KD, Kleschen MJ, Oleson EB, Dehoff MH, Schwartz MK et al (2005). Behavioral and neurochemical phenotyping of Homer1 mutant mice: possible relevance to schizophrenia. Genes Brain Behav 4: 273-288. (Pubitemid 41002403)
89. Tanda K, Nishi A, Matsuo N, Nakanishi K, Yamasaki N, Sugimoto T et al (2009). Abnormal social behavior, hyperactivity, impaired remote spatial memory, and increased D1-mediated dopaminer-gic signaling in neuronal nitric oxide synthase knockout mice. Mol Brain 2: 19.
90. Thomsen M, Wess J, Fulton B, Fink-Jensen A, Caine S (2010). Modulation of prepulse inhibition through both M1 and M4 muscarinic receptors in mice. Psychopharmacology 208: 401-416.
91. Urigüen L, Garća-Fuster M, Callado L, Morentin B, La Harpe R, Casadó V et al (2009). Immunodensity and mRNA expression of A2A adenosine, D2 dopamine, and CB1 cannabinoid receptors in postmortem frontal cortex of subjects with schizophrenia: effect of antipsychotic treatment. Psychopharmacology 206: 313-324.
92. Urigüen L, Pérez-Rial S, Ledent C, Palomo T, Manzanares J (2004). Impaired action of anxiolytic drugs in mice deficient in cannabinoid CB1 receptors. Neuropharmacology 46: 966-973. (Pubitemid 38471950)
93. Van Sickle MD, Duncan M, Kingsley PJ, Mouihate A, Urbani P, Mackie K et al (2005). Identification and functional characterization of brainstem cannabinoid CB2 receptors. Science 310: 329-332. (Pubitemid 41457202)
94. Vaugeois JM, Passera G, Zuccaro F, Costentin J (1997). Individual differences in response to imipramine in the mouse tail suspension test. Psychopharmacology 134: 387-391. (Pubitemid 28023413)
95. Wiedholz LM, Owens WA, Horton RE, Feyder M, Karlsson RM, Hefner K et al (2008). Mice lacking the AMPA GluR1 receptor exhibit striatal hyperdopaminergia and 'schizophrenia-related' behaviors. Mol Psychiatry 13: 631-640. (Pubitemid 351704934)
96. Willi R, Weinmann O, Winter C, Klein J, Sohr R, Schnell L et al (2010). Constitutive genetic deletion of the growth regulator Nogo-A induces schizophrenia-related endophenotypes. J Neurosci 30: 556-567.
97. Wolinsky TD, Swanson CJ, Smith KE, Zhong H, Borowsky B, Seeman P et al (2007). The Trace Amine 1 receptor knockout mouse: an animal model with relevance to schizophrenia. Genes Brain Behav 6: 628-639. (Pubitemid 47476185)
98. Wynn JK, Green MF, Sprock J, Light GA, Widmark C, Reist C et al (2007). Effects of olanzapine, risperidone and haloperidol on prepulse inhibition in schizophrenia patients: a double-blind, randomized controlled trial. Schizophr Res 95: 134-142. (Pubitemid 47313638)
99. Yamasaki N, Maekawa M, Kobayashi K, Kajii Y, Maeda J, Soma M et al (2008). Alpha-CaMKII deficiency causes immature dentate gyrus, a novel candidate endophenotype of psychiatric disorders. Mol Brain 1: 6.
100. Yamashita M, Fukushima S, Shen H-w, Hall FS, Uhl GR, Numachi Y et al (2006). Norepinephrine transporter blockade can normalize the prepulse inhibition deficits found in dopamine transporter knockout mice. Neuropsychopharmacology 31: 2132-2139. (Pubitemid 44413190)
101. Yao JK, van Kammen DP, Reddy RD, Keshavan MS, Schmid PC, Berdyshev EV et al (2002). Elevated endocannabinoids in plasma from patients with schizophrenia. Biol Psychiatry 51: S64-S65.
102. Zammit S, Allebeck P, Andreasson S, Lundberg I, Lewis G (2002). Self reported cannabis use as a risk factor for schizophrenia in Swedish conscripts of 1969: historical cohort study. BMJ 325: 1199.